Session 421: Immune Checkpoints and Immunotherapy

Day 2: Morning, Friday, July 26, 2019

Place: Room K, 2nd Floor

Chair: Dr. James Legg, SVP Research, Crescendo Biologics, UK

Chair’s Introduction

Keynote Speech

Title: Discovery and Activity of Bempegaldesleukin, A CD122-preferential Cytokine Agonist

Dr. Jonathan Zalevsky, Senior Vice President, CSO, Research, Nektar Therapeutics, USA

Title: Topoisomerase I Inhibitor, Irinotecan, Depletes Regulatory T Cells and Up-regulates MHC Class I and PD-L1 Expression, Resulting in a Supra-additive Antitumor Effect When Combined with Anti-PD-L1 Antibodies

Dr. Masamichi Sugimoto, Research Scientist, Product Research Department, Kamakura Laboratory, Chugai Pharmaceutical Co., Ltd., Japan

Title: CB307: A Novel CD137/4-1BB Agonist Humabody Therapeutic for PSMA Positive Tumours
Dr. James Legg, SVP Research, Crescendo Biologics, UK

Title: An Anti-PD-1 Antibody with or without FcγRI-Binding Has Profound Impact on Biological Functions
Dr. Kang Li, SVP, Head of Biologics, BeiGene, China

Title: Combination Immunotherapy to Overcome Resistance to Cancer Treatments

Dr. Raymond Tesi, CEO/CMO, INmune Bio Inc, USA

Coffee Break

Title: Novel Oncolytic Herpesvirus Agency Embodying Immunotherapeutic Genes Encoding IL-12 and Anti-PD-1 Antibody

Dr. Grace Zhou, CEO/CSO, ImmVira Co., Ltd., China

Title: First-in-class Antibody Targeting Soluble NKG2D Ligand sMIC Enhances Immune Checkpoint Blockade Therapy and Eliminates Therapy Associated Colon Toxicity

Dr. Jennifer Wu, Mary and Patrick Scanlan Professor, Feinberg School of Medicine and Lurie Cancer Center, Northwestern University, USA

Title: Beating Cancer with Adoptive Transfer of Programmed T Cell Immunotherapy

Dr. Richard Koya, Associate Director of the Center for Immunotherapy; Director of the Vector Development & Production Facility; Associate Professor of Oncology and Immunology; Roswell Park Comprehensive Cancer Center, Center for Immunotherapy, USA

Session 422: Therapeutic Antibodies and Vaccines

Day 2: Afternoon, Friday, July 26, 2019

Place: Room J, 2nd Floor

Chair: Dr. Yaakov Naparstek, Chairman of Medicine, Hadassah University Hospital, Israel

Chair’s Introduction

Keynote Speech

Title: Blincyto®: Lessons Learnt from the First Approved BiTE® Antibody Construct for Cancer Therapy

Dr. Benno Rattel, Executive Director Research, Amgen Research, Germany

Title: Development of Novel Glucocorticoid Payloads for Use in Antibody Drug Conjugates for the Treatment of Inflammatory Diseases

Dr. Amy Han, Director of R&D Chemistry, Regeneron Pharmaceuticals, Inc., USA

Title: Discovery of a Novel Anti-CD47 Antibody with Anti-cancer Therapeutic Potential and Minimal RBC Binding
Dr. Xiao Feng, President of R&D Center, GeneScience Pharmaceuticals, China

Title: Selection of Monoclonal Antibodies Targeting MERS-CoV through a Human Synthetic Fab Phage Display Library Panning and Their Characterization

Dr. Dae Young Kim, Principal Researcher, Head of Discovery & Optimization Division, New Drug Development Center, Osong Medical Innovation Foundation, South Korea

Title: High Quality Antibodies for Therapeutic Applications

Dr. Vera Molkenthin, Chief Scientist, AbCheck s.r.o., Czech Republic

Coffee Break

Title: Expression of Rabies Virus Glycoprotein in Mammalian Cells for Rabies Vaccine Development

Dr. Le Sun, Co-founder, Any-go Technology, USA; Adjunct Professor of Beijing Normal University, China

Dr. Yaakov Naparstek, Chairman of Medicine, Hadassah University Hospital, Israel

Title: For the Eye Altering, Alters the All

Dr. Anne-Marie Bogaert, Departement of Nephrology/Dialysis, AZ Glorieux Ronse, Belgium

Title: Application of Carp Glycophorin from Red Blood Cell Membranes as an Antibiotic Reagent
Dr. Takahiko Aoki, Professor, Laboratory of Quality in Marine Products, Faculty of Bioresources, Mie University, Japan

Title: Biotechnology Antiproteinase Vaccine in the Experiment

Dr. Valentina A. Divocha, Lugansk State Medical University, Ukraine

Session 423: Therapeutic Proteins and Peptides

Day 3: Morning, Saturday, July 27, 2019

Place: Room K, 2nd Floor

Chair: Dr. Immanuel Lerner, CEO/Co-founder, Pepticom LTD, Israel

Chair’s Introduction

Title: Application of Artificial Intelligence in Peptide Drug Discovery: Opportunities and Challenges

Dr. Immanuel Lerner, CEO/Co-founder, Pepticom LTD, Israel

Title: Bioactive Peptides Hidden in Human Salivary Proteins
Dr. Eiichi Saitoh, Professor, Graduate School of Technology, Niigata Institute of Technology, Japan

Coffee Break

Title: The Peptide Targeting MRI and Chemotherapy for Hepato-pancreatic Cancer Treatment
Dr. Chin-Tarng Lin, Emeritus Professor, College of Medicine, National Taiwan University, Taiwan

Title: Effect of F11R Derived Peptide, P4D on Vascular Remodeling

Dr. Anna Babinska, Research Associate Professor, State University of New York, USA

Title: Design of Orally Effective Peptides Based on the Structure of Bioactive Peptides Derived from Natural Proteins

Dr. Masaaki Yoshikawa, Professor Emeritus, Kyoto University, Japan

Session 424: Cell and Gene Therapy

Day 3: Afternoon, Saturday, July 27, 2019

Place: Room J, 2nd Floor

Chair: Dr. Zhenhong Li, Senior Director of Analytics, RegenxBio Inc., USA 

Chair’s Introduction

Keynote Speech

Title: Gene Therapy - A New Era of Personalized Medicine - Promises, Bottlenecks and Technologies

Dr. Jeffrey Hung, CCO and GM, Vigene Biosciences, USA

Title: Analytical Technology Used in the Latest Development of Gene Therapy Candidates

Dr. Zhenhong Li, Senior Director of Analytics, RegenxBio Inc., USA

Title: Gene Therapy and Safety during Manufacturing
Mr. Richard Denk, Head Sales Containment, SKAN AG, Switzerland

Title: Development of Tumor Infiltrating Lymphocytes for Treatment of Solid Tumors

Dr. Zelanna Goldberg, SVP, Clinical Development, Iovance Biotherapeutics, USA

Coffee Break

Title: E-selectin/AAV Gene Therapy Promotes Therapeutic Angiogenesis in Mouse Limb Ischemia and Gangrene Model

Dr. Zhao-Jun Liu, Associate Professor, DeWitt-Daughtry Family Department of Surgery, Division of Vascular Surgery, University of Miami Miller School of Medicine, USA

Title: Possible Effects of Bone Marrow Derived Mesenchymal Stem Cell Therapy in Rotenone Induced Rat Model of Parkinsonism Versus Its Conditioned Medium

Dr. Soha Abdelkawi Abdelwahab, Assistant Professor, Histology Department, Faculty of Medicine, Minya University, Egypt

Session 425: Gene Therapy: Translational Development and Clinical Application

Day 3: Afternoon, Saturday, July 27, 2019

Place: Room K, 2nd Floor

Chair: Dr. Noriyuki Kasahara, Professor and Alvera L. Kan Endowed Chair, Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco (UCSF), USA

Chair’s Introduction

Title: Retroviral Replicating Vectors for Gene Therapy and Immunotherapy of Cancer: Translational and Clinical Studies Leading to International Phase III Trial

Dr. Noriyuki Kasahara, Professor and Alvera L. Kan Endowed Chair, Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco (UCSF), USA

Title: Antitumor Factors Associated with Oncolytic Virus C-REV (Formerly HF10)

Dr. Hideki Kasuya, Professor & Chair, Department of Cancer Immune Therapy and Associate Dean for International Affairs, Nagoya University, Japan

Title: Targeting the P53 Pathway is a Therapeutic Strategy for Mesothelioma

Dr. Masatoshi Tagawa, Professor, Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba; Clinical Attending Physician, Funabashi Orthopaedic Hospital, Funabashi City; Visiting Scientist, Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan

Title: Development of Infectivity Selective Oncolytic Adenovirus for Systemic Cancer Therapy

Dr. Masato Yamamoto, Professor and Eugene C. and Gail V. Sit Chair in Pancreatic and Gastrointestinal Cancer Research, Departments of Surgery & Pharmacology, University of Minnesota, USA

Title: Mesenchymal Stem Cells as Adenoviral Replication Permissive Biological Factory Enhances Systemic Delivery Efficiency of Oncolytic Adenovirus to Hapetocellular Carcinoma

Dr. Chae-Ok Yun, Professor, Department of BioEngineering, Hanyang University, South Korea;  Adjunct Professor, Department of Pharmaceutical Chemistry, University of Utah, USA

Title: Recent Progress of Gene Therapy in Cardiovascular Diseases

Dr. Hironori Nakagami, Professor, Osaka University Graduate School of Medicine, Japan

Title: Gene and Cell Therapy in Europe: Progress, Prospects, and Perspective

Ms. Gaëlle Jamar, Association Accelerator & Manager, European Society of Gene & Cell Therapy (ESGCT); Wats.On Consultancy Ltd, UK